This statistic depicts the percentage of biopharma companies that said they had select secondary financial priorities, according to a survey conducted during summer 2018. According to the survey, 67 percent of respondents indicated that research and development is a secondary priority for their company.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Deloitte. (October 26, 2018). Percentage of biopharma companies that have select secondary financial priorities as of 2018 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 20, 2026, from /statistics/954432/secondary-biopharma-investments/
Deloitte. "Percentage of biopharma companies that have select secondary financial priorities as of 2018." Chart. October 26, 2018. ÌÇÐÄÆƽâ°æ. Accessed July 20, 2026. /statistics/954432/secondary-biopharma-investments/
Deloitte. (2018). Percentage of biopharma companies that have select secondary financial priorities as of 2018. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 20, 2026. /statistics/954432/secondary-biopharma-investments/
Deloitte. "Percentage of Biopharma Companies That Have Select Secondary Financial Priorities as of 2018." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 26 Oct 2018, /statistics/954432/secondary-biopharma-investments/
Deloitte, Percentage of biopharma companies that have select secondary financial priorities as of 2018 ÌÇÐÄÆƽâ°æ, /statistics/954432/secondary-biopharma-investments/ (last visited July 20, 2026)
Percentage of biopharma companies that have select secondary financial priorities as of 2018 [Graph], Deloitte, October 26, 2018. [Online]. Available: /statistics/954432/secondary-biopharma-investments/
